Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan

Research and Development

2025.12.24

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; “Sumitomo Pharma”) and RACTHERACo., Ltd. (Head Office: C…

RACTHERA Inc. Corporate Website Launch Announcement

Company

2025.12.24

RACTHERA Inc. has launched its corporate website. We are a joint venture established through joint investment …